耳鳴り(Tinnitus):治療薬開発のグローバルパイプライン分析(2014年上半期)

◆英語タイトル:Tinnitus - Pipeline Review, H1 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5117IDB
◆発行日:2014年6月15日
◆調査対象地域:グローバル
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[耳鳴り(Tinnitus):治療薬開発のグローバルパイプライン分析(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Tinnitus – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Tinnitus – Pipeline Review, H1 2014’, provides an overview of the Tinnitus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tinnitus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Tinnitus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Tinnitus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tinnitus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tinnitus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tinnitus Overview 7
Therapeutics Development 8
Pipeline Products for Tinnitus – Overview 8
Pipeline Products for Tinnitus – Comparative Analysis 9
Tinnitus – Therapeutics under Development by Companies 10
Tinnitus – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Tinnitus – Products under Development by Companies 16
Tinnitus – Companies Involved in Therapeutics Development 17
Merz Pharma GmbH & Co. KgaA 17
Auris Medical AG 18
Knopp Biosciences LLC 19
Otonomy, Inc. 20
Synphora AB 21
Flexion Therapeutics, Inc. 22
Tinnitus – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 31
esketamine hydrochloride – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
JB-004/A – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
neramexane mesylate – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drug For Tinnitus – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
gacyclidine – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AUT-00063 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AUT-3 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule To Activate Kv7 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
acamprosate – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Tinnitus – Recent Pipeline Updates 43
Tinnitus – Dormant Projects 47
Tinnitus – Product Development Milestones 48
Featured News & Press Releases 48
Mar 31, 2014: Published Analysis Confirms Positive Results from Auris Medical’s Phase IIb Study with AM-101 in Treatment of Acute Inner Ear Tinnitus 48
Sep 09, 2013: Second Phase II Clinical Trial Confirms Safety and Efficacy Trends for Auris Medical AG’s AM-101 in Treatment of Acute Peripheral Tinnitus 49
Jun 04, 2013: Autifony Therapeutics Initiates Phase I Trial Of AUT-00063 For Treatment Of Hearing Loss And Tinnitus 50
May 17, 2013: Auris Medical Announces Presentation Of Safety Results From AM-101 Clinical Development At 7th International TRI Tinnitus Conference 50
Apr 30, 2013: Auris Medical Selects Medidata Clinical Cloud To Support New Tinnitus Research 51
Feb 12, 2013: Auris Medical Completes Enrollment In Phase II Study Of AM-101 For Treatment Of Acute Peripheral Tinnitus 52
Aug 10, 2012: Auris Medical Completes Enrolment In First Stage Of AM-101 TACTT1 Study 52
Jun 26, 2012: Auris Medical Presents Key Results From Phase IIb Study Of AM-101 At International TRI Tinnitus Conference 53
Oct 17, 2011: Auris Medical Reports Positive Results From Phase IIb Trial With AM-101 For Treatment Of Acute Inner Ear Tinnitus 54
Feb 28, 2011: Auris Medical Starts Enrolment In First US Clinical Trial With AM-101 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 57
Disclaimer 57

List of Tables
Number of Products under Development for Tinnitus, H1 2014 8
Number of Products under Development for Tinnitus - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Tinnitus - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2014 17
Tinnitus - Pipeline by Auris Medical AG, H1 2014 18
Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2014 19
Tinnitus - Pipeline by Otonomy, Inc., H1 2014 20
Tinnitus - Pipeline by Synphora AB, H1 2014 21
Tinnitus - Pipeline by Flexion Therapeutics, Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 30
Tinnitus Therapeutics - Recent Pipeline Updates, H1 2014 43
Tinnitus - Dormant Projects, H1 2014 47

List of Figures
Number of Products under Development for Tinnitus, H1 2014 8
Number of Products under Development for Tinnitus - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Molecule Type, H1 2014 30

*** 掲載企業 ***

Merz Pharma GmbH & Co. KgaA
Auris Medical AG
Knopp Biosciences LLC
Otonomy, Inc.
Synphora AB
Flexion Therapeutics, Inc.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5117IDB )"耳鳴り(Tinnitus):治療薬開発のグローバルパイプライン分析(2014年上半期)" (英文:Tinnitus - Pipeline Review, H1 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。